安罗替尼维持治疗广泛期小细胞肺癌的疗效及对患者血清CEC、ES水平的影响  

Effects of Anlotinib Maintenance Treatment on Extensive Small Cell Lung Cancer and Serum CEC and ES Levels

作　　者：徐红燕[1] 王文静[1] 姜秀 栾云雁 郭辉[1] 孙志 宋成村[1] 殷军蕾 高绍荣[1] XU Hong-yan;WANG Wen-jing;JIANG Xiu;LUAN Yun-yan;GUO Hui;SUN Zhi;SONG Cheng-cun;YIN Jun-lei;GAO Shao-rong(Department 3 of Chemotherapy,Weihai Municipal Hospital,Weihai 264200,China)

机构地区：[1]威海市立医院化疗三科,山东威海264200

出　　处：《南昌大学学报（医学版）》2022年第1期61-65,共5页Journal of Nanchang University：Medical Sciences

摘　　要：目的观察安罗替尼维持治疗广泛期小细胞肺癌患者的疗效及患者血清循环内皮细胞(CEC)和内皮抑素(ES)水平的变化。方法收集80例广泛期小细胞肺癌患者的临床数据,根据治疗方式的不同分为2组:观察组和对照组,每组各40例;观察组服用安罗替尼;对照组给予依托泊苷治疗。比较2组疗效、生存期、生活质量KPS评分、不良反应,定期采集2组患者血清检测神经元特异性烯醇化酶(NSE)、CEC、ES水平。结果观察组治疗总有效率高于对照组(62.50%比35.00%,P<0.05);观察组中位无进展生存期长于对照组[(6.1±0.6)个月比(3.8±0.7)个月,P<0.05];观察组的不良反应(甲状腺功能减退症、腹泻、蛋白尿、高血压、手足皮肤反应、皮疹、血促甲状腺激素升高)均高于对照组(均P<0.05),但2组总不良反应率和3/4级不良反应率无显著性差异(均P>0.05)。观察组治疗4和6周期的NSE、CEC水平均低于对照组(均P<0.05),ES水平均高于对照组(均P<0.01),KPS评分均优于对照组(均P<0.05)。结论安罗替尼维持治疗广泛期小细胞肺癌具有较好的疗效,可降低患者血清CEC水平,升高血清ES水平。Objective To observe the clinical efficacy of anlotinib maintenance treatment in extensive small cell lung cancer(SCLC)and its effects on circulating endothelial cells(CEC)and endothelial inhibitor(ES)levels.Methods Clinical data of 80 patients with extensive SCLC were collected.These patients were randomly assigned to receive either anlotinib(observation group,n=40)or etoposide(control group,n=40).The efficacy,survival,KPS score and adverse reactions were compared between the two groups.Serum neuron-specific enolase(NSE),CEC and ES levels were detected periodically in both groups.Results The total effective rate in the observation group was higher than that in the control group(62.50%vs 35.00%,P<0.05).The median progression-free survival in the observation group was longer than that in the control group[(6.1±0.6)months vs(3.8±0.7)months,P<0.05].The incidences of hypothyroidism,diarrhea,proteinuria,hypertension,hand-foot skin reaction,rash,and thyroid stimulating hormone elevation in the observation group were higher than those in the control group(P<0.05).However,there were no significant differences in the total adverse reaction rate and the grade 3/4 adverse reaction rate between the two groups(P>0.05).Compared with the control group,anlotinib reduced NSE and CEC levels,increased ES concentration and improved KPS score after 4 and 6 cycles of treatment(P<0.05 or P<0.01).Conclusion Anlotinib maintenance treatment can effectively reduce CEC level and increase ES concentration in patients with extensive SCLC.

关 键 词：安罗替尼 维持治疗 小细胞肺癌 循环内皮细胞 内皮抑素 

分 类 号：R734.2[医药卫生—肿瘤]